Business Context and Reporting Period
Aldeyra Therapeutics, Inc. filed this Form 8-K on January 14, 2015, to report the completion of a private placement of equity securities. The company is a Delaware corporation headquartered in Lexington, MA.
Key Financial Metrics
- Gross Proceeds: Approximately $7.79 million.
- Shares Issued: 1,113,080 shares of common stock.
- Purchase Price: $7.00 per share.
- Warrants Issued: Warrants to purchase up to 1,113,080 shares at an exercise price of $9.50 per share, expiring January 14, 2018.
- Transaction Costs: Approximately $545,410 paid to Laidlaw & Company (UK) Ltd. as placement agent compensation.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The transaction was executed pursuant to a Purchase Agreement dated January 12, 2015, and closed on January 14, 2015.
Outlook, Risks, and Contingencies
- Registration Rights: Aldeyra must file a registration statement for the resale of shares and warrant-issuable shares within 75 days of closing and have it declared effective within 120 days (or 150 days if a full SEC review occurs).
- Liquidated Damages: If the company fails to meet registration covenants, it must pay investors 1% of their purchase price per month in cash until cured.
- Warrant Redemption: The company has the option to redeem warrants for $0.001 per share if the stock price exceeds $20.00 for 15 consecutive trading days and average daily volume exceeds 50,000 shares.
- Regulatory Status: Securities were sold under Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the effective date of the registration statement filed for the resale of the new shares and warrants.
- Confirm the dilution impact of the 1,113,080 new shares and the potential 1,113,080 shares from warrant exercises.
- Review the full text of the Registration Rights Agreement (Exhibit 10.43) for specific covenants and liquidated damages triggers.
- Monitor the company's cash burn rate to assess the runway provided by the $7.79 million in gross proceeds.